<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861000</url>
  </required_header>
  <id_info>
    <org_study_id>190064</org_study_id>
    <secondary_id>19-M-0064</secondary_id>
    <nct_id>NCT03861000</nct_id>
  </id_info>
  <brief_title>Title: Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)</brief_title>
  <official_title>Evaluation of a Novel PET Radioligand for Phosphodiesterase-4D (PDE4D)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
      The brain enzyme phosphodiesterase-4D (PDE4D) may affect thinking and depression. Drugs with&#xD;
      some radioactivity can attach to enzymes and be seen on a scan. Researchers want to test a&#xD;
      new radioactive drug, 11C-T-1650, to measure PDE4D in the brain and body. They also want to&#xD;
      see if the new drug BPN14770 blocks 11C-T-1650 from the brain. They want to learn more about&#xD;
      psychiatric disorders and possible treatments.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      To study how well 11C-T-1650 helps show PDE4D on a scan and to see if BPN14770 blocks it.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      Healthy adults at least 18 years old&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Participants will be screened in other protocols.&#xD;
&#xD;
      Some participants will have 1 body PET scan.&#xD;
&#xD;
      Some participants will have 2 brain PET scans and 1 brain MRI within 1 year.&#xD;
&#xD;
      Some participants (ages 18 55) will:&#xD;
&#xD;
      Have 3 brain PET scans and 1 MRI&#xD;
&#xD;
      Take BPN14770 by mouth twice daily for 3 7 days&#xD;
&#xD;
      Have blood and urine tests&#xD;
&#xD;
      Have a follow-up physical exam and heart test&#xD;
&#xD;
      PET (positron emission tomography) scans will take 2 3 hours. Participants will:&#xD;
&#xD;
      Have a thin plastic tube (catheter) placed in an arm vein by needle.&#xD;
&#xD;
      Get a small amount of 11C-T-1650 injected via catheter. Another catheter may be placed to&#xD;
      draw blood.&#xD;
&#xD;
      Lie quietly on a bed that slides into a donut-shaped scanner without sleeping. They may get a&#xD;
      short break.&#xD;
&#xD;
      Have heart and vital signs monitored.&#xD;
&#xD;
      Have blood and urine tests.&#xD;
&#xD;
      Learn about drinking fluids and urinating after the scan&#xD;
&#xD;
      MRI (magnetic resonance imagining) scans will take 30 60 minutes:&#xD;
&#xD;
      Participants will lie on a table that slides into a metal cylinder in a magnetic field.&#xD;
&#xD;
      Sponsoring Institute: National Institute of Mental Health&#xD;
&#xD;
      ...&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective&#xD;
&#xD;
      Phosphodiesterase type 4 (PDE4) metabolizes 3 &lt;=,5 &lt;=-cyclic adenosine monophosphate (cAMP),&#xD;
      thereby terminating this second messenger. PDE4 is selective to cAMP over cyclic guanosine&#xD;
      monophosphate. PDE4 has four isozymes A, B, C, and D and basic studies suggest that type D&#xD;
      (PDE4D) may play a key role in cognitive function and depression. That is, PDE4D inhibitors&#xD;
      are expected to improve cognitive function and depressive symptoms.&#xD;
&#xD;
      In collaboration with Tetra Discovery Partners, we have developed a PET ligand, 11C-T-1650,&#xD;
      to selectively image PDE4D. This type D selective ligand was developed based on 3D structural&#xD;
      differences between PDE4D and PDE4 type B (PDE4B) Our PET studies using 11C-T-1650 in&#xD;
      nonhuman primate have shown promising results, and we now seek to evaluate it in in healthy&#xD;
      subjects.&#xD;
&#xD;
      This study has three primary objectives. First, we will determine whether the uptake of&#xD;
      11C-T-1650 in the brain reflects the distribution of PDE4D, as demonstrated by blocking with&#xD;
      a PDE4D selective compound BPN14770, being developed by Tetra Discovery Partners for treating&#xD;
      cognitive disorders including depression. Second, we will measure binding site occupancy of&#xD;
      BPN14770 administered at doses that may be used in clinical trials. Third, we will measure&#xD;
      the test/retest reproducibility of brain uptake quantified by kinetic modeling and using&#xD;
      arterial blood samples.&#xD;
&#xD;
      Study Population&#xD;
&#xD;
      Healthy adult female and male volunteers (age greater than or equal to 18) will have either&#xD;
      brain (n = 30) or whole body imaging (n = 10).&#xD;
&#xD;
      Design&#xD;
&#xD;
        -  Phase 1: We will begin with whole body scanning in a single human subject using up to 10&#xD;
           mCi 11C-T-1650 The aim of this first scan will be to detect a tracer that&#xD;
           disproportionately accumulates in a single radiosensitive organ, such as the gonads. If&#xD;
           we confirm that radioactivity is fairly widely distributed in the body, higher&#xD;
           activities may be injected.&#xD;
&#xD;
        -  Phase 2: Fifteen healthy subjects will have three brain PET scans using 20 mCi of&#xD;
           11C-T-1650. Scan 1 will serve as the baseline scan for comparison to enzyme occupancy&#xD;
           studies (Scan 2 and - Scans 2 and 3 will be enzyme occupancy studies using the PDE4D&#xD;
           selective medication BPN14770.Scans 2 and Scan 3 will be performed approximately 90-180&#xD;
           min after the first dose of BPN14770 and after three-day administration, respectively.&#xD;
           Scan 3 will be performed approximately 90-180 min after the last dose of the three-day&#xD;
           administration of BPN14770. The dose of BPN14770 is 50 mg BID for three days, and a&#xD;
           single dose on the fourth day. Comparison between Scan 1 and 2 provides accurate&#xD;
           measurement of nonspecific binding of 11C-T-1650. Comparison between Scan 1 and 3&#xD;
           provides enzyme occupancy at a stable plasma concentration of BPN14770 based on Phase&#xD;
           1/2 clinical trials performed by Tetra Discovery Partners. Blood samples will be&#xD;
           measured for BPN14770 levels.&#xD;
&#xD;
        -  Phase 3: To obtain dosimetry information, we will perform a whole body PET scan using&#xD;
           11C-T-1650 (20 mCi) in up to nine healthy subjects.&#xD;
&#xD;
        -  Phase 4: Fifteen healthy subjects will have two brain PET scans using 20 mCi of&#xD;
           11C-T-1650 to study test/retest reproducibility of the PET measurement. BPN14770 will&#xD;
           not be administered in Phases 1, 3 or 4.&#xD;
&#xD;
      Outcome Measures&#xD;
&#xD;
      For whole body imaging, organ uptake will be quantified as a Standardized Uptake Value (SUV),&#xD;
      which normalizes for injected activity and body weight. For Scan 1 and 2 of Phase 2 and all&#xD;
      scans of Phase 4, uptake will be quantified as total distribution volume (VT) calculated with&#xD;
      kinetic modeling and serial concentrations of parent radioligand in arterial plasma. For Scan&#xD;
      3 of Phase 3, brain uptake (SUV) normalized to plasma concentrations of 11C-T-1650 will be&#xD;
      used to measure radioligand binding because the interval between Scan 2 and 3 is too short to&#xD;
      repeat placing arterial line. From VT or normalized SUV, occupancy of BPN14770 and&#xD;
      nonspecific binding of 11C-T-1650 will be measured. Occupancy of PDE4D will be compared to&#xD;
      blood levels of BPN14770.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2019</start_date>
  <completion_date type="Actual">February 11, 2020</completion_date>
  <primary_completion_date type="Actual">February 11, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Whole Brain Total Distribution Volume (VT) - Baseline</measure>
    <time_frame>120 minutes after the start of the first scan</time_frame>
    <description>To determine whether the uptake of 11C-T-1650 in brain reflects the distribution of PDE4D</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Whole Brain Total Distribution Volume (VT)-1st Blocked</measure>
    <time_frame>120 minutes after the start of the second scan</time_frame>
    <description>To determine whether the uptake of 11C-T-1650 in brain reflects the distribution of PDE4D</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard UptakeValue (SUV) Area Under the Curve (AUC) (60-120min)-Baseline Whole Brain</measure>
    <time_frame>120 minutes after the start of the scan</time_frame>
    <description>Measure binding site occupancy of BPN14770 administered at doses that may be used in clinical trials.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard UptakeValue (SUV) Area Under the Curve (AUC) (60-120min)-1st Blocked Whole Brain</measure>
    <time_frame>120 minutes after the start of the first scan</time_frame>
    <description>Measure binding site occupancy of BPN14770 administered at doses that may be used in clinical trials.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Standard UptakeValue (SUV) Area Under the Curve (AUC) (60-120min)-2nd Blocked Whole Brain</measure>
    <time_frame>120 minutes after the start of the first scan</time_frame>
    <description>Measure binding site occupancy of BPN14770 administered at doses that may be used in clinical trials.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Whole body PET Scan with intravenous 11C-T-1650</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mCi of 11C-T-1650 given intravenously once followed by a Whole Body PET scan. This was done for whole body dosimetry calculations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brain PET scan with 11C-T-1650 and blocking with BPN14770</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[C-11]T-1650</intervention_name>
    <description>radio-labeled drug</description>
    <arm_group_label>Brain PET scan with 11C-T-1650 and blocking with BPN14770</arm_group_label>
    <arm_group_label>Whole body PET Scan with intravenous 11C-T-1650</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BPN14770</intervention_name>
    <description>selective compound</description>
    <arm_group_label>Brain PET scan with 11C-T-1650 and blocking with BPN14770</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:&#xD;
&#xD;
        All phases&#xD;
&#xD;
          1. Age greater than equal 18.&#xD;
&#xD;
          2. Able to give written informed consent.&#xD;
&#xD;
          3. Medically and psychiatrically healthy.&#xD;
&#xD;
          4. Enrolled in 01-M-0254 The Evaluation of Participants with Mood and Anxiety Disorders&#xD;
             and Healthy Volunteers (PI: Dr. Carlos Zarate) or 17-M-0181 Recruitment and&#xD;
             Characterization of Healthy Research Volunteers for NIMH Intramural Studies (PI: Dr.&#xD;
             Joyce Chung).&#xD;
&#xD;
        Additional inclusion criterial for Phase 2&#xD;
&#xD;
          1. Age less than or equal to 55.&#xD;
&#xD;
          2. Body mass index between 18 kg/m2 to 32 kg/m2, inclusive, and body weight of greater&#xD;
             than equal 50 kg (110 pounds).&#xD;
&#xD;
          3. Female subjects must be surgically sterile (bilateral tubal ligation, hysterectomy, or&#xD;
             bilateral oophorectomy at least 6 months prior to dosing of BPN14770), at least two&#xD;
             years post-menopausal, or willing to use two barrier methods of contraception from&#xD;
             initial screening until one month after taking the last dose of study drug.&#xD;
&#xD;
          4. Male subjects must be willing to inform female partners of their participation in the&#xD;
             study and must agree to use adequate contraceptive methods (vasectomy performed at&#xD;
             least 6 months prior to dosing BPN14770 or use at least one barrier method of birth&#xD;
             control).&#xD;
&#xD;
        EXCLUSION CRITERIA:&#xD;
&#xD;
        All phases&#xD;
&#xD;
          1. Clinically significant laboratory abnormalities based on the following tests&#xD;
             (performed under screening protocol 01-M-0254 or 17-M-0181): CBC; acute care panel;&#xD;
             hepatic panel; mineral panel; urinalysis; urine drug screen; urine pregnancy test&#xD;
             (females); and lipid panel; hepatitis panel (A, B, C); syphilis screening test; total&#xD;
             protein; uric acid;creatine kinase; cholesterol; thyroid panel; prothrombin and&#xD;
             partial prothrombin tests; and EKG.&#xD;
&#xD;
          2. Have a brain disease (such as multiple sclerosis or stroke).&#xD;
&#xD;
          3. Any current Axis I diagnosis, based on interview and self-reporting performed under&#xD;
             screening protocol 01-M-0254 or 17-M-0181.&#xD;
&#xD;
          4. Positive HIV test.&#xD;
&#xD;
          5. Current or past history of significant cardiovascular, cerebrovascular, pulmonary,&#xD;
             renal, or liver disease. Stable, well-controlled hypertension and hyperlipidemias are&#xD;
             allowed.&#xD;
&#xD;
          6. Taking psychotropic drugs (i.e. benzodiazepines or antidepressants) including sedative&#xD;
             antihistamines; moderate to strong inhibitors or inducers (i.e. fluconazole or&#xD;
             ciprofloxacin) of any CYP450 enzyme. A complete listing of such inhibitors or inducers&#xD;
             may be found in Attachment 1, List of P450 inhibitors.&#xD;
&#xD;
          7. Recent exposure to radiation related to research (e.g., PET from other research) that,&#xD;
             when combined with this study, would be above the allowable limits.&#xD;
&#xD;
          8. Inability to lie flat on camera bed for at least two hours.&#xD;
&#xD;
          9. Pregnancy or breastfeeding.&#xD;
&#xD;
         10. Positive screen for drugs of abuse or cotinine (at screen or upon admission), or a&#xD;
             positive alcohol result (upon admission).&#xD;
&#xD;
         11. Current use of psychiatric medications.&#xD;
&#xD;
         12. NIMH employees and staff or immediate family members of NIMH employee/staff.&#xD;
&#xD;
        Additional exclusion criterial for Phase 2 and 4&#xD;
&#xD;
          1. coagulation disorder;&#xD;
&#xD;
          2. thrombocytopenia;&#xD;
&#xD;
          3. Found to have inadequate collateral circulation of the radial artery&#xD;
&#xD;
          4. Are unable to have an MRI scan (e.g., pacemakers or other implanted electrical&#xD;
             devices, brain stimulators, dental implants, aneurysm clips (metal clips on the wall&#xD;
             of a large artery), metallic prostheses (including metal pins and rods, heart valves,&#xD;
             and cochlear implants), permanent eyeliner, implanted delivery pumps, or shrapnel&#xD;
             fragments, metal fragments in the eye)&#xD;
&#xD;
        Additional exclusion criterial for Phase 2&#xD;
&#xD;
          1. Marked bradycardia (heart rate 45 beats per minute [bpm]) or tachycardia (heart rate&#xD;
             110 bpm) based on supine ECG values obtained at Screening, before the first dose of&#xD;
             BPN14770 on the day of the study. Out-of-range vital signs may be repeated once at&#xD;
             each eligibility assessment (prior to the start of dosing).&#xD;
&#xD;
          2. History of hematological disorders (e.g., thrombocytopenia) in the immediate family&#xD;
             (i.e., parents and siblings).&#xD;
&#xD;
          3. Clinically important or significant conduction abnormalities on single ECG (including&#xD;
             QTc interval 450 msec) or evidence or history of long QT syndrome. This exclusion&#xD;
             applies to the ECGs obtained at Screening, before the first dose of BPN14770 on the&#xD;
             day of the study.&#xD;
&#xD;
          4. Current or past history of gastric or duodenal ulcers or other diseases of the&#xD;
             gastrointestinal tract that could interfere with absorption of study drug. Note:&#xD;
             Subjects with a history of appendectomy or cholecystectomy may be enrolled.&#xD;
&#xD;
          5. Active acute or chronic infectious diseases.&#xD;
&#xD;
          6. Any history of alcohol or drug abuse within the previous year prior to the Screening&#xD;
             visit (per the current edition of the Diagnostic and Statistical Manual of Mental&#xD;
             Disorders, 5th Edition: DSM-5), or regular (daily) consumption of alcohol exceeding&#xD;
             two bottles of beer, or the equivalent amount of other forms of alcohol (1 serving =&#xD;
             12 oz beer, 5.0 oz wine, or 1.5 oz distilled spirits).&#xD;
&#xD;
          7. Unwilling to abstain from alcohol within 72 hours of before the first dose of&#xD;
             BPN14770.&#xD;
&#xD;
          8. Currently ingest nicotine in any way (including smoking cigarettes, vaping, and via&#xD;
             patch), or have ingested any nicotine products within the past 3 months.&#xD;
&#xD;
          9. Participation in other clinical studies involving investigational drug within the&#xD;
             previous 30 days prior to the first day of the study.&#xD;
&#xD;
         10. Unwilling to forgo donation of blood or blood products (including plasma) during the 8&#xD;
             weeks before the first day of the study.&#xD;
&#xD;
         11. History of allergy to penicillin or sulfonamides, or any other clinically significant&#xD;
             drug allergy that includes symptoms such as shortness of breath, rash, or edema.&#xD;
&#xD;
         12. A suicidal ideation intensity score of 2 or higher per screening C-SSRS assessment&#xD;
             and/or any suicidal behavior within the past 30 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert B Innis, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Mental Health (NIMH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?A_2019-M-0064.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <results_first_submitted>January 22, 2021</results_first_submitted>
  <results_first_submitted_qc>January 22, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2021</results_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy Control Subjects</keyword>
  <keyword>PET Imaging</keyword>
  <keyword>Receptor Occupancy</keyword>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 3, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03861000/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A single subject was enrolled only for pre-study whole body dosimetry calculations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Brain PET Scan With 11C-T-1650 and Blocking With BPN14770</title>
          <description>Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.</description>
        </group>
        <group group_id="P2">
          <title>Whole Body PET Scan With Intravenous 11C-T-1650</title>
          <description>10 mCi of 11C-T-1650 given intravenously once followed by a Whole Body PET scan. This was done for whole body dosimetry calculations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Brain PET Scan With 11C-T-1650 and Blocking With BPN14770</title>
          <description>Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.</description>
        </group>
        <group group_id="B2">
          <title>Whole Body PET Scan With Intravenous 11C-T-1650</title>
          <description>10 mCi of 11C-T-1650 given intravenously once followed by a Whole Body PET scan. This was done for whole body dosimetry calculations.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="1"/>
            <count group_id="B3" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Whole Brain Total Distribution Volume (VT) - Baseline</title>
        <description>To determine whether the uptake of 11C-T-1650 in brain reflects the distribution of PDE4D</description>
        <time_frame>120 minutes after the start of the first scan</time_frame>
        <population>The analyses included only those subjects who completed brain 11C-T-1650 and oral 50 mg BID of BPN14770 (twice/day, 7 times in total)</population>
        <group_list>
          <group group_id="O1">
            <title>Brain PET Scan With 11C-T-1650 and Blocking With BPN14770</title>
            <description>Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.</description>
          </group>
        </group_list>
        <measure>
          <title>Whole Brain Total Distribution Volume (VT) - Baseline</title>
          <description>To determine whether the uptake of 11C-T-1650 in brain reflects the distribution of PDE4D</description>
          <population>The analyses included only those subjects who completed brain 11C-T-1650 and oral 50 mg BID of BPN14770 (twice/day, 7 times in total)</population>
          <units>mL x cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Whole Brain Total Distribution Volume (VT)-1st Blocked</title>
        <description>To determine whether the uptake of 11C-T-1650 in brain reflects the distribution of PDE4D</description>
        <time_frame>120 minutes after the start of the second scan</time_frame>
        <population>The analyses included only those subjects who completed brain 11C-T-1650 and oral 50 mg BID of BPN14770 (twice/day, 7 times in total)</population>
        <group_list>
          <group group_id="O1">
            <title>Brain PET Scan With 11C-T-1650 and Blocking With BPN14770</title>
            <description>Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.</description>
          </group>
        </group_list>
        <measure>
          <title>Whole Brain Total Distribution Volume (VT)-1st Blocked</title>
          <description>To determine whether the uptake of 11C-T-1650 in brain reflects the distribution of PDE4D</description>
          <population>The analyses included only those subjects who completed brain 11C-T-1650 and oral 50 mg BID of BPN14770 (twice/day, 7 times in total)</population>
          <units>mL x cm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (60-120min)-Baseline Whole Brain</title>
        <description>Measure binding site occupancy of BPN14770 administered at doses that may be used in clinical trials.</description>
        <time_frame>120 minutes after the start of the scan</time_frame>
        <population>The analyses included only those subjects who completed brain 11C-T-1650 and oral 50 mg BID of BPN14770 (twice/day, 7 times in total)</population>
        <group_list>
          <group group_id="O1">
            <title>Brain PET Scan With 11C-T-1650 and Blocking With BPN14770</title>
            <description>Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.</description>
          </group>
        </group_list>
        <measure>
          <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (60-120min)-Baseline Whole Brain</title>
          <description>Measure binding site occupancy of BPN14770 administered at doses that may be used in clinical trials.</description>
          <population>The analyses included only those subjects who completed brain 11C-T-1650 and oral 50 mg BID of BPN14770 (twice/day, 7 times in total)</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102.1" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (60-120min)-1st Blocked Whole Brain</title>
        <description>Measure binding site occupancy of BPN14770 administered at doses that may be used in clinical trials.</description>
        <time_frame>120 minutes after the start of the first scan</time_frame>
        <population>The analyses included only those subjects who completed brain 11C-T-1650 and oral 50 mg BID of BPN14770 (twice/day, 7 times in total)</population>
        <group_list>
          <group group_id="O1">
            <title>Brain PET Scan With 11C-T-1650 and Blocking With BPN14770</title>
            <description>Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.</description>
          </group>
        </group_list>
        <measure>
          <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (60-120min)-1st Blocked Whole Brain</title>
          <description>Measure binding site occupancy of BPN14770 administered at doses that may be used in clinical trials.</description>
          <population>The analyses included only those subjects who completed brain 11C-T-1650 and oral 50 mg BID of BPN14770 (twice/day, 7 times in total)</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.719845" spread="20.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (60-120min)-2nd Blocked Whole Brain</title>
        <description>Measure binding site occupancy of BPN14770 administered at doses that may be used in clinical trials.</description>
        <time_frame>120 minutes after the start of the first scan</time_frame>
        <population>The analyses included only those subjects who completed brain 11C-T-1650 and oral 50 mg BID of BPN14770 (twice/day, 7 times in total)</population>
        <group_list>
          <group group_id="O1">
            <title>Brain PET Scan With 11C-T-1650 and Blocking With BPN14770</title>
            <description>Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.</description>
          </group>
        </group_list>
        <measure>
          <title>Standard UptakeValue (SUV) Area Under the Curve (AUC) (60-120min)-2nd Blocked Whole Brain</title>
          <description>Measure binding site occupancy of BPN14770 administered at doses that may be used in clinical trials.</description>
          <population>The analyses included only those subjects who completed brain 11C-T-1650 and oral 50 mg BID of BPN14770 (twice/day, 7 times in total)</population>
          <units>SUV x min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.77384" spread="19.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>24 hours</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Brain PET Scan With 11C-T-1650 and Blocking With BPN14770</title>
          <description>Baseline brain PET scan (scan 1) with 20 mCi of 11C-T-1650 given intravenously, followed by a second Brain PET scan (scan 2) 90-180 minutes after first dose administration of BPN14770 50mg given orally. A third brain PET scan (scan 3) is performed after the last dose of BPN14770. 20 mCi of 11C-T-1650 is given intravenously with each PET scan. BPN14770 50mg given orally twice a day for a total of seven doses. BPN14770 is a PDE4D-inhibitor.</description>
        </group>
        <group group_id="E2">
          <title>Whole Body PET Scan With Intravenous 11C-T-1650</title>
          <description>10 mCi of 11C-T-1650 given intravenously once followed by a Whole Body PET scan. This was done for whole body dosimetry calculations.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Robert Innis</name_or_title>
      <organization>National Institute of Mental Health</organization>
      <phone>+1 301 693 2979</phone>
      <email>innisr@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

